A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer
PHASE4CompletedINTERVENTIONAL
Enrollment
100
Participants
Timeline
Start Date
April 30, 2003
Study Completion Date
June 30, 2005
Conditions
Cancer of Prostate
Interventions
DRUG
leuprolide acetate
Trial Locations (1)
92404
San bernardino Urological Associates Medical Group, San Bernardino
All Listed Sponsors
lead
San Bernardino Urological Associates Medical Group Inc
OTHER
NCT00220194 - A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer | Biotech Hunter | Biotech Hunter